Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies To the Editor: Biologic switching has become a common practice in dermatology clinics. Although outcomes of switching between older generation biologics have been extensively studied, the effectiveness and safety of switching patients between interleukin (IL) 17A antagonists is unknown. As such, dermatologists might be hesitant to attempt therapy with a second IL-17A antagonist, electing instead to try an alternative biologic. Therefore, we aimed to investigate the likelihood that secukinumab nonresponders will respond to ixekizumab. Furthermore, we assessed whether or not individuals who experienced an adverse event (AE) to secukinumab experienced the same fate with ixekizumab.
We conducted a Canadian multicenter retrospective study of patients $18 years of age with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] $10 at baseline) and treated with ixekizumab 80-mg therapy after discontinuation of secukinumab 300 mg. Responders were patients who achieved a 75% reduction in PASI (PASI 75) or physician global assessment (PGA) of 0 (clear) or 1 (almost clear) when PASI was not documented.
Patient demographics and clinical outcomes of the 17 patients who met inclusion criteria are summarized in Table I . Of the 17 patients who were secukinumab nonresponders, 15 (88.2%) responded to ixekizumab following 12 weeks of treatment. This was similar to the IL-17Aenaive patients treated with ixekizumab in randomized controlled trials (UNCOVER-1, 89.1; UNCOVER-2, 89.7; UNCOVER-3, 87.3%).
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In subset analysis, all primary nonresponders to secukinumab (n ¼ 4) achieved PASI 75 or PGA 0/1 after 12 weeks of ixekizumab treatment compared with 8 of 9 (88.9%) secondary nonresponders and 3 of 4 (75%) patients who stopped secukinumab because of intolerance or a nondrug-related reason (Fig 1) . Of note, PASI 75 response was shown to be strongly associated with the reason for switching for individuals who switched between tumor necrosis factor (TNF) inhibitors. [3] [4] [5] Piaserico et al suggested individuals who experienced secondary loss of efficacy to one TNF-inhibitor or stopped treatment due to an AE were more likely to achieve PASI 75 at week 12 than those who were primary nonresponders. Our findings suggest the same might not be true for IL-17A antagonists, where efficacy outcomes did not correlate with reason for secukinumab discontinuation. Similarly, duration of secukinumab therapy had no affect on efficacy outcomes, with 75.0% (3/4), 90.0% (9/10), and 100% (3/3) of patients responding to ixekizumab after 4-26 week, 27-52 week, and $53 weeks of secukinumab treatment, respectively. Overall, these results suggest that a large proportion of secukinumab nonresponders who switch to ixekizumab will experience an improved clinical response regardless the reason or timing of secukinumab discontinuation.
In our patient population, 6 (35.3%) patients experienced $1 AE while on secukinumab. Of these 6 patients, 3 (50%) went on to experience an AE to ixekizumab. Three patients who did not experience an AE on secukinumab did so on ixekizumab. In total, 6 (35.3%) patients experienced $1 AE to ixekizumab compared with 58.4% of IL-17Aenaive patients in randomized controlled trials. 2 Reported AEs are summarized in Table I . Of the 3 patients who experienced an AE to both secukinumab and ixekizumab, 1 subject sustained an identical AE to both treatments: a drug eruption with lymphocytic and eosinophilic infiltrates. This patient was also the 1 individual within the entire cohort who discontinued ixekizumab because of an AE.
The results of our study suggest that 1) ixekizumab appears to be a promising treatment option with good clinical outcome when treating moderate-tosevere plaque psoriasis patients with prior exposure to secukinumab and 2) not all patients who experience an AE to secukinumab will experience the same fate with ixekizumab. Although these findings might help improve dermatologist decision-making when switching between IL-17A antagonists, prospective studies with larger sample sizes are required to draw definitive conclusions. Efficacy outcomes for 17 patients treated with secukinumab followed by ixekizumab for moderate-to-severe plaque psoriasis. Primary nonresponders did not achieve PASI 75 at any point throughout the secukinumab treatment period. Secondary nonresponders achieved PASI 75 after 12 weeks of treatment, however, experienced loss of efficacy thereafter. PASI 75, 75% Reduction in Psoriasis Area and Severity Index.
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Dermatology faculty and residents' perspectives on the dermatology residency application process: A nationwide survey
To the Editor: According to recent estimates, dermatology has the most expensive residency application process, with an approximate total cost per US senior applicant of $10,781. 1, 2 This high cost is due, in part, to the fact that dermatology has the highest median number of Electronic Residency Application Service applications submitted per US senior applicant (ie, 91). 3 We sought to examine dermatology faculty and residents' perspectives on the current residency application process, as well as identify potential modifications to the application process that are widely supported and, thus, likely to be implemented in the future.
Two anonymous, electronic surveys (1 for faculty and 1 for residents) were designed using Survey Monkey. The Oregon Health and Science University Institutional Review Board approved both surveys. The surveys were distributed nationwide via the Association of Professors of Dermatology (APD) e-mail listserv in July 2017. We collected the responses during a 3-week period; at which point, data were downloaded on Excel (Microsoft, Redmond, Washington) for analysis.
We received responses from 174 dermatology residents, and 180 out of 368 APD faculty members (48.9% response rate) (Tables I and II) . Nearly 75% of dermatology faculty recommend that applicants apply to \60 dermatology residency programs, whereas [70% of dermatology residents applied to $60 programs (Tables I and II) . Nearly 80% of both faculty and residents believe that applicants who interview via videoconferencing are not considered equally when compared with those who interview in-person. Seventy percent of faculty and [80% of residents support aims to coordinate interview dates by geographic region, and ;75% of faculty were willing to work with other programs to implement interview coordination.
The results of this nationwide survey have several important implications. First, the significant discordance between the high rate at which residents (ie, recent applicants) applied to $60 programs, despite most faculty recommending applying to \60 programs, likely reflects perceptions about the highly competitive nature of matching into dermatology. Recent Association of American Medical Colleges data indicate that there is minimal additive benefit of applying to [40 programs with respect to the outcome of matching into dermatology. 4 This data would be important to incorporate into faculty advising to reduce this gap and application costs. Second, most of both faculty and residents believe that applicants who interview via videoconferencing are not considered equally to those who interview in-person, thereby questioning the utility of offering videoconference interviews as an alternative to limit applicants' expenses. 5 Residents and faculty support the coordination of interview dates by geographic region, and most faculty are willing to work with other programs to implement this change. The coordination of interviews represents a realistic opportunity to 1) lessen applicants' expenses and stress associated with frequent travel; 2) limit programs from offering conflicting interview dates; 3) reduce interview cancellations due to weather, transportation issues, etc; and 4) decrease applicants' carbon footprint.
One important implication of this study is that the current dermatology residency application process, with its exorbitantly high cost, disadvantages applicants from lower socioeconomic backgrounds and is a barrier to applying to dermatology. Given that dermatology is also one of the least diverse specialties, second only to orthopedic surgery, 5 it should be an explicit aim of our specialty to promote inclusivity. Future qualitative studies will be important to better understand the perspectives of dermatology applicants and to identify strategies for both applicants and residency programs to lower costs and remove barriers to the application process.
